COVID-19 vaccine trials and sex-disaggregated data
Expert Rev Vaccines
.
2022 Mar;21(3):285-288.
doi: 10.1080/14760584.2022.2015331.
Epub 2021 Dec 19.
Authors
Musaddique Hussain
1
,
Mehwish Fatima
1
,
Shahid Muhammad Iqbal
1
,
Muhammad Asif
1
,
Malik Saadullah
2
,
Kashif-Ur-Rehman
1
,
Imran Mukhtar
1
,
Imran Ahmad Khan
1
,
Sajida Parveen
1
,
Tehreem Fayyaz
1
,
Najia Shabbir
1
,
Aisha Kanwal
1
,
Saira Shaukat
1
,
Mobeen Fatima
1
,
Nadia Ikram
1
,
Abdul Majeed
3
,
Farzana Parveen
3
,
Muhammad Tariq
4
,
Muhammad Qasim Barkat
5
,
Ling-Hui Zeng
6
,
Ximei Wu
5
Affiliations
1
Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
2
Department of Pharmaceutical Chemistry, Government College University, Faisalabad, Pakistan.
3
Faculty of Pharmacy, Bahauddin Zakariya University, Multan Pakistan.
4
Lahore Pharmacy College (LMDC), Lahore, Pakistan.
5
Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou City, China.
6
Department of Pharmacology, Zhejiang University City College, Hangzhou, China.
PMID:
34894982
PMCID:
PMC8726001
DOI:
10.1080/14760584.2022.2015331
No abstract available
Publication types
Editorial
MeSH terms
COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
SARS-CoV-2
Sex Factors
Substances
COVID-19 Vaccines
Grants and funding
This paper was not funded.